secwatch.observer — SEC 8-K summary
======================================

Issuer:     Odyssey Health, Inc. (ODYY)
CIK:        0001626644
Form:       8-K
Filed at:   2023-12-29T23:59:59+00:00
Accession:  0001683168-23-009136
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Odyssey Health closes asset sale of brain illness drug candidates to Oragenics for $1M cash and 8M preferred shares
--------------------------------------------------------------------------------

- Sold drug candidates for mild traumatic brain injury and Niemann Pick Disease Type C, plus proprietary powder formulation and nasal delivery device.
- Received $1M in cash plus 8M shares of convertible Series F Preferred Stock from Oragenics.
- Closing conditions included shareholder approvals from both Odyssey and Oragenics; no material adverse change required.
- Odyssey previously disclosed the Purchase Agreement in an October 5, 2023 8-K.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1626644/000168316823009136/0001683168-23-009136-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1626644/000168316823009136/odyssey_8k.htm
  HTML page:      https://secwatch.observer/filing/0001683168-23-009136

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer